Cerecor’s (CERC) “Buy” Rating Reiterated at LADENBURG THALM/SH SH

LADENBURG THALM/SH SH reaffirmed their buy rating on shares of Cerecor (NASDAQ:CERC) in a research report sent to investors on Friday, AnalystRatings.com reports. The brokerage currently has a $10.00 price objective on the stock.

A number of other equities analysts also recently commented on CERC. Maxim Group restated a buy rating and set a $10.00 price objective on shares of Cerecor in a research note on Friday, November 15th. ValuEngine downgraded Cerecor from a buy rating to a hold rating in a research report on Thursday, November 28th. Finally, HC Wainwright reiterated a buy rating and set a $12.00 price objective (up previously from $11.00) on shares of Cerecor in a research report on Monday, December 2nd. One equities research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company’s stock. Cerecor has an average rating of Buy and an average target price of $10.67.

CERC opened at $4.00 on Friday. The company has a debt-to-equity ratio of 0.78, a quick ratio of 0.71 and a current ratio of 0.73. The firm has a 50-day moving average price of $3.37 and a two-hundred day moving average price of $3.95. Cerecor has a 1-year low of $2.71 and a 1-year high of $7.65.

Cerecor (NASDAQ:CERC) last announced its quarterly earnings data on Thursday, November 14th. The company reported ($0.07) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.13) by $0.06. Cerecor had a negative net margin of 113.66% and a negative return on equity of 121.32%. The business had revenue of $5.61 million for the quarter, compared to analyst estimates of $5.15 million. As a group, equities research analysts predict that Cerecor will post -0.5 earnings per share for the current year.

A number of large investors have recently added to or reduced their stakes in CERC. Wells Fargo & Company MN acquired a new position in Cerecor in the 2nd quarter worth about $853,000. JPMorgan Chase & Co. raised its holdings in Cerecor by 612.7% in the 2nd quarter. JPMorgan Chase & Co. now owns 72,670 shares of the company’s stock valued at $355,000 after buying an additional 62,473 shares during the last quarter. Charles Schwab Investment Management Inc. bought a new position in Cerecor in the 2nd quarter valued at approximately $288,000. Bank of New York Mellon Corp raised its holdings in Cerecor by 294.9% in the 2nd quarter. Bank of New York Mellon Corp now owns 57,428 shares of the company’s stock valued at $312,000 after buying an additional 42,885 shares during the last quarter. Finally, Northern Trust Corp boosted its position in Cerecor by 47.4% during the 2nd quarter. Northern Trust Corp now owns 55,971 shares of the company’s stock worth $304,000 after buying an additional 17,999 shares during the period. 60.84% of the stock is owned by institutional investors and hedge funds.

About Cerecor

Cerecor Inc, a pharmaceutical company, focuses on pediatric health care. Its lead product portfolio includes prescribed dietary supplements, such as Poly-Vi-Flor and Tri-Vi-Flor; and prescription drugs, such as Millipre, Ulesfia, Karbinal ER, AcipHex Sprinkle, and Cefaclor for oral suspension, as well as Flexichamber a medical device.

Read More: Analyzing a company’s cash flow statement

Receive News & Ratings for Cerecor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerecor and related companies with MarketBeat.com's FREE daily email newsletter.